Cargando…

Performance of Antipseudomonal β-Lactams on the Accelerate PhenoTest BC Kit against a Collection of Pseudomonas aeruginosa Isolates

Detalles Bibliográficos
Autores principales:	Sikorski, Aaron, Shamsheyeva, Alena, Gamage, Dulini, Oppermann, Niels, Bhalodi, Amira A., Humphries, Romney M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111152/ https://www.ncbi.nlm.nih.gov/pubmed/33148710 http://dx.doi.org/10.1128/JCM.01781-20

Ejemplares similares

2144. Performance of 2019 CLSI Ciprofloxacin Breakpoint Antimicrobial Susceptibility Testing Algorithms for Enterobacteriaceae and Pseudomonas aeruginosa Directly from Positive Blood Culture on the Accelerate Pheno™ System
por: Shamsheyeva, Alena, et al.
Publicado: (2019)

Improving outcomes and antibiotic stewardship (IOAS) for patients with Gram-positive bloodstream infections through use of rapid testing: a quasi-experimental multicentre study of the Accelerate PhenoTest™ BC Kit
por: MacVane, Shawn H., et al.
Publicado: (2021)

Real-World Impact of the Accelerate PhenoTest BC Kit on Patients With Bloodstream Infections in the Improving Outcomes and Antimicrobial Stewardship Study: A Quasiexperimental Multicenter Study( )
por: Bhalodi, Amira A, et al.
Publicado: (2021)

Multicenter Evaluation of the Accelerate PhenoTest BC Kit for Rapid Identification and Phenotypic Antimicrobial Susceptibility Testing Using Morphokinetic Cellular Analysis
por: Pancholi, Preeti, et al.
Publicado: (2018)

Prospective Evaluation of Accelerate Pheno™ System (AXDX) Version 1.1 for Reducing Turn-Around-Time (TAT) in Identification/Antimicrobial Susceptibility Testing (ID/AST) of Gram-Negative Bacilli (GNB) from Positive Blood Cultures (+BC) using AXDX PhenoTest™ BC Kits
por: Willey, Barbara M, et al.
Publicado: (2017)

Mortality in patients with carbapenem-resistant Pseudomonas aeruginosa with and without susceptibility to traditional antipseudomonal β-lactams
por: Howard-Anderson, Jessica, et al.
Publicado: (2021)

Antipseudomonal β-Lactams Resistance in Iran
por: Rabiei, Mohammad Mahdi, et al.
Publicado: (2020)

Relation between Resistance to Antipseudomonal β-Lactams and ampC and mexC Genes of Pseudomonas aeruginosa
por: Rezaei, Fatemeh, et al.
Publicado: (2016)

Clinical impact of the accelerate PhenoTest® BC system on patients with gram-negative bacteremia and high risk of antimicrobial resistance: a prospective before-after implementation study
por: Brosh-Nissimov, Tal, et al.
Publicado: (2023)

2175. In vitro Potency of Ceftolozane/Tazobactam and Other Antipseudomonal β-Lactams Against P. aeruginosa
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2018)

Retrospective Evaluation of Accelerate Pheno™ System (AXDX, Version 1.1) for Identification/Antimicrobial Susceptibility Testing (ID/AST) of Gram-Negative Bacilli (GNB) including Carbapenemase-Producing Organisms (CPO) from Seeded Blood Culture Bottles (SBCB) Tested using AXDX PhenoTest(TM) BC Kits
por: Willey, Barbara M, et al.
Publicado: (2017)

834. Clinical Outcomes with Carbapenem-Resistant Pseudomonas aeruginosa that Retain Susceptibility to Traditional Antipseudomonal β-lactams: Atlanta, 2016-2018
por: Howard-Anderson, Jessica, et al.
Publicado: (2020)

2290. Carbapenem vs. Piperacillin–tazobactam Definitive Therapy for Patients with Bloodstream Infections Due to Ceftriaxone Not Susceptible Escherichia coli or Klebsiella species
por: MacVane, Shawn H, et al.
Publicado: (2019)

Effective implementation of the Accelerate Pheno™ system for positive blood cultures
por: Humphries, Romney, et al.
Publicado: (2019)

Evaluation of the Empiric use of Levofloxacin in Combination with Antipseudomonal Β-Lactams for the Treatment of Pneumonia
por: Bachna, Jon, et al.
Publicado: (2017)

Impact on time to active antimicrobial therapy with 24-hour pharmacist review of Accelerate Pheno BC Kit results
por: Kinn, Patrick M., et al.
Publicado: (2022)

Clinical Outcomes of Antipseudomonal vs. Non-Antipseudomonal Therapy in Patients with Osteomyelitis
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

The Art of War with Pseudomonas aeruginosa: Targeting Mex Efflux Pumps Directly to Strategically Enhance Antipseudomonal Drug Efficacy
por: Avakh, Asiyeh, et al.
Publicado: (2023)

1587. Comparative In Vitro Antipseudomonal Activity of Ceftolozane/Tazobactam Against Pseudomonas aeruginosa Isolates from Children with Cystic Fibrosis
por: Kanwar, Neena, et al.
Publicado: (2019)

125. Induction of Resistance Against Antipseudomonal Agents: Comparison of Novel b-Lactam/b-Lactamase Inhibitor (BL/BLI) Combinations and Other b-lactam Agents
por: Castanheira, Mariana, et al.
Publicado: (2022)

Comparative efficacy and safety of antipseudomonal β-lactams for pediatric febrile neutropenia: A systematic review and Bayesian network meta-analysis
por: Tan, Xinmei, et al.
Publicado: (2021)

Piperacillin–Tazobactam Plus Vancomycin-Associated Acute Kidney Injury in Adults: Can Teicoplanin or Other Antipseudomonal Beta-Lactams Be Remedies?
por: Aslan, Abdullah Tarık, et al.
Publicado: (2022)

Association between duration of antipseudomonal beta-lactam therapy and Clostridioides difficile infections in monomicrobial Enterobacterales bloodstream infections at an academic medical center
por: Hawkins, Audry M., et al.
Publicado: (2022)

An evaluation of antipseudomonal dosing on the incidence of treatment failure
por: Hawkins, Brandon K, et al.
Publicado: (2021)

Evaluating the Nephrotoxicity of Area-under-the-Curve-Based Dosing of Vancomycin with Concomitant Antipseudomonal Beta-Lactam Antibiotics: A Systematic Review and Meta-Analysis
por: Chiu, Chia-Yu, et al.
Publicado: (2023)

The Effect of Decreased Antipseudomonal Drug Consumption on Pseudomonas aeruginosa Incidence and Antimicrobial Susceptibility Profiles over 9 Years in a Lebanese Tertiary Care Center
por: El-Basst, Rima, et al.
Publicado: (2023)

Quorum Quenching: A Potential Target for Antipseudomonal Therapy
por: Hemmati, Fatemeh, et al.
Publicado: (2020)

Pheno 2019
Publicado: (2019)

Synergistic Antipseudomonal Effects of Synthetic Peptide AMP38 and Carbapenems
por: Rudilla, Héctor, et al.
Publicado: (2016)

β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects
por: Glen, Karl A., et al.
Publicado: (2021)

1600. Susceptibility of β-Lactam-Resistant Pseudomonas aeruginosa to Other β-Lactams: Is There Truly a Lack of Cross-Resistance?
por: Patel, Twisha S, et al.
Publicado: (2019)

2812. Clinical Impact of the Ceftolozane-Tazobactam Shortage on Difficult-To-Treat Resistant Pseudomonas aeruginosa Infections at an Academic Medical Center
por: Vance, Mary K, et al.
Publicado: (2023)

Utilizing Monte Carlo Simulations to Optimize Institutional Empiric Antipseudomonal Therapy
por: Tennant, Sarah J., et al.
Publicado: (2015)

Determinants of empirical antipseudomonal antibiotic prescription for adults with pneumonia in the emergency department
por: Angrill, Nuria, et al.
Publicado: (2020)

KDEON WK-11: A short antipseudomonal peptide with promising potential
por: Casciaro, Bruno, et al.
Publicado: (2022)

Pheno 2005 Symposium
Publicado: (2005)

PHENO 2001 Symposium
Publicado: (2001)

Future Perspectives at HL-LHC Prospects for Pheno26, Pheno31, and beyond
por: Jeanty, Laura
Publicado: (2021)

Trimeric Tobramycin/Nebramine Synergizes β-Lactam Antibiotics against Pseudomonas aeruginosa
por: Dhiman, Shiv, et al.
Publicado: (2023)

NtrBC Regulates Invasiveness and Virulence of Pseudomonas aeruginosa During High-Density Infection
por: Alford, Morgan A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6detevus6s3sp01rodm6k1il50